Abstract Library

#2980 Metabolic Dysregulation and Circadian Clock in Cellular Models of Neuroendocrine Tumors

Introduction: The circadian clock genes encode transcription factors whose interaction with nuclear receptors allows the regulation of cellular metabolism.The invalidation of the genes of the clock core is associated with the development of many endocrine diseases including neuroendocrine cancer. Recently, the family of transcriptional coactivators PGC-1a has been identified as a key element in the integration of cellular metabolic state with the circadian clock. PRC, as a member of the PGC-1 family, was able to interact with several transcription factors, including the CLOCK factor. The specific induction of this PRC factor by the cell cycle, to modulate the energy function, the MAPkinase pathway and the expression of microRNAs, makes it a key factor in the metabolic adaptation of cancer cells.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Savagner F

Authors: Savagner F, Le Pennec S,

Keywords: Metabolism, Circadian clock, cell models,

#2834 Tumor-Promoting Effects of the Transcriptional Regulator CUX1 in PanNET

Introduction: Previously, we identified CUX1 as mediator of metastatic behaviour and poor differentiation in human insulinomas. CUX1 mediated tumor-promoting functions via enhancing proliferation, resistance to apoptosis and angiogenesis in-vitro and in-vivo.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Weißbach J

Authors: Weißbach J, Schmitz R, Haybäck J, Perren A, Blank A,

Keywords: CUX1, RIP1Tag2, DAPK1, Apoptosis, Tumor Progression,

#2817 METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors

Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Glasberg J

Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,

Keywords: neuroendocrine tumors, metformin, clinical trial,

#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV

Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Łowczak A, Kolasińska-Ćwikła A, Osowiecka K, Ćwikła J, Rzepko R,

Keywords: Large cell neuroendocrine cancer, Overall survival, Progression-free survival,

#2275 Analysis of Gene Expression Patterns of Rectum Neuroendocrine Tumors (NET) Versus Healthy Tissue Reveals Alterations in the MAPK and WNT Signaling Pathways

Introduction: The neuroendocrine tumors (NETs) of the rectum are rare but increasing in incidence, by means of improved endoscopic techniques and histological reporting. They often occur as small polypoid lesions and G1, and in most cases an incidental finding at endoscopy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Briest F

Authors: Briest F, Hummel M, Grabowski P, Arsenic R,

Keywords: rectum neuroendocrine tumors, NET, MAP kinase, gene expression analysis, Wnt signaling,